Solit DB - Search Results

1

Tumour lineage shapes BRCA-mediated phenotypes.

Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. Jonsson P, et al. Among authors: solit db. Nature. 2019 Jul;571(7766):576-579. doi: 10.1038/s41586-019-1382-1. Epub 2019 Jul 10. Nature. 2019. PMID: 31292550 Free PMC article.

2

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. Solit DB, et al. Clin Cancer Res. 2002 May;8(5):986-93. Clin Cancer Res. 2002. PMID: 12006510

3

Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.

Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Solit DB, et al. Cancer Res. 2003 May 1;63(9):2139-44. Cancer Res. 2003. PMID: 12727831

4

Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.

Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK. Smaletz O, et al. Among authors: solit db. Ann Oncol. 2003 Oct;14(10):1518-24. doi: 10.1093/annonc/mdg415. Ann Oncol. 2003. PMID: 14504052 Free article. Clinical Trial.

5

Hsp90 as a therapeutic target in prostate cancer.

Solit DB, Scher HI, Rosen N. Solit DB, et al. Semin Oncol. 2003 Oct;30(5):709-16. doi: 10.1016/s0093-7754(03)00346-4. Semin Oncol. 2003. PMID: 14571418 Review.

6

Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.

Solit DB, Morris M, Slovin S, Curley T, Schwartz L, Larson S, Kattan MW, Hartley-Asp B, Scher HI, Kelly WK. Solit DB, et al. Cancer. 2003 Nov 1;98(9):1842-8. doi: 10.1002/cncr.11754. Cancer. 2003. PMID: 14584065 Free article. Clinical Trial.

7

Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.

Enmon R, Yang WH, Ballangrud AM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G. Enmon R, et al. Among authors: solit db. Cancer Res. 2003 Dec 1;63(23):8393-9. Cancer Res. 2003. PMID: 14679001

8

High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.

Morris MJ, Smaletz O, Solit D, Kelly WK, Slovin S, Flombaum C, Curley T, Delacruz A, Schwartz L, Fleisher M, Zhu A, Diani M, Fallon M, Scher HI. Morris MJ, et al. Cancer. 2004 May 1;100(9):1868-75. doi: 10.1002/cncr.20185. Cancer. 2004. PMID: 15112267 Free article.

9

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.

Solit DB, She Y, Lobo J, Kris MG, Scher HI, Rosen N, Sirotnak FM. Solit DB, et al. Clin Cancer Res. 2005 Mar 1;11(5):1983-9. doi: 10.1158/1078-0432.CCR-04-1347. Clin Cancer Res. 2005. PMID: 15756024

10

BRAF mutation predicts sensitivity to MEK inhibition.

Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. Solit DB, et al. Nature. 2006 Jan 19;439(7074):358-62. doi: 10.1038/nature04304. Epub 2005 Nov 6. Nature. 2006. PMID: 16273091 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

375 results

Search Page